Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1948061
                    [Title] => Case for rivaroxaban and aspirin for pad gets stronger
                    [Summary] => Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS trial, which included more than 7,000 patients whose primary diagnosis at study entry was stable PAD.
                    [DatePublished] => 2019-09-01 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

rivaroxaban

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1948061
                    [Title] => Case for rivaroxaban and aspirin for pad gets stronger
                    [Summary] => Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS trial, which included more than 7,000 patients whose primary diagnosis at study entry was stable PAD.
                    [DatePublished] => 2019-09-01 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Case for rivaroxaban and aspirin for pad gets stronger

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 1, 2019 - 12:00am

Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS...

Opinion